Patients with primary myelofibrosis who have anemia, no deletion of 5q, and serum erythropoietin below 500 mU/mL — in whom a prior anemia-directed treatment line has not achieved the expected response.
Erythropoiesis-stimulating agents were the initial approach for anemia with serum EPO <500 mU/mL. Escalation to the current line is triggered when that therapy did not achieve the target anemia response: transfusion cessation in transfusion-dependent patients, or a hemoglobin increase of 2 g/dL or greater in transfusion-independent patients.
After failure of erythropoiesis-stimulating agents, the approach shifts toward enrollment in anemia-oriented clinical trials. The full structured protocol — including eligibility criteria, sequencing, and available options — is accessible via the link below.
DOI: 10.1182/blood.2022017423